vs-7375
vs-7375: developed by 1 company · 4 clinical trials tracked.
vs-7375 evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could vs-7375 → VSTM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Verastem, Inc. (VSTM) Non-Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma… | Phase 1/Phase 2 |
Clinical Trials (4)
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)
Primary endpoint: Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)
Primary endpoint: Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)
Primary endpoint: Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors
Primary endpoint: Part A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375
Frequently asked questions
Who is developing vs-7375?
vs-7375 is being developed by Verastem, Inc..
How many clinical trials involve vs-7375?
BioSniper tracks 4 clinical trials involving vs-7375.